Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib — SAFIR 03

Breast Cancer Stage IV Clinical Trial

Official title:
A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations

Status Recruiting

Clinical Trial Summary

After an initial screening phase (SAFIR 03 - SCREENING) to identify patients with blood circulating mutated-PIK3CA tumours persistent, patients will be enrolled in the treatment phase of SAFIR 03 (SAFIR 03 - ARRIBA) that was designed as a randomised, open-label, multicentre, phase II study, for comparison of alpelisib to ribociclib in combination with fulvestrant (as the continuation of the CDK4/6 inhibitor-fulvestrant strategy) in terms of progression-free survival (PFS).

Clinical Trial Description

INDICATION The population eligible to the screening phase is composed of all women or men with HR+, HER2- metastatic breast cancer who are eligible for first-line treatment with a cyclin-dependent kinases (CDK) 4/6 inhibitor combined with fulvestrant (and a luteinizing hormone realeasing hormone (LH-RH) analogue in men and premenopausal women) in the context of the standard healthcare management. The screening will identify patients with high risk of relapse on any CDK4/6 inhibitor thanks to ctDNA kinetic between baseline and 4 weeks of treatment. The purpose is to early adapt the therapeutic intervention for ctDNA no drop patient to prevent from relapse. This study will propose an intervention for PIK3CA mutated patients with alpelisib vs. ribociclib. Other therapeutic approaches might be proposed to patients with wild type PIK3CA through other protocols. The randomised study phase will include patients with persistent mutations on exons 4, 9 or 20* of PIK3CA ctDNA after 4 weeks of treatment with any CDK4/6 inhibitor-fulvestrant in first-line setting. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05625087
Study type	Interventional
Source	UNICANCER
Contact	Fabrice ANDRE
Phone	+33 (0)1 42 11 43 71
Email	fabrice.andre@gustaveroussy.fr
Status	Recruiting
Phase	Phase 2
Start date	October 19, 2023
Completion date	June 2030

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04469127` - A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.	Phase 1/Phase 2
Withdrawn	`NCT03032614` - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients	Phase 2
Terminated	`NCT04123704` - Sitravatinib in Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05377047` - Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer	N/A
Completed	`NCT03304210` - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer	Phase 1
Completed	`NCT05054374` - A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer	Phase 1/Phase 2
Recruiting	`NCT05559528` - BRaziLian outcomE for metAStatic breasT Cancer
Active, not recruiting	`NCT05090358` - Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05033925` - Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients	Phase 1/Phase 2
Recruiting	`NCT03401359` - The Resistance and Immune Response to Palbociclib in Breast Cancer	N/A
Active, not recruiting	`NCT03870919` - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients	N/A
Not yet recruiting	`NCT05860907` - Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis	Phase 4
Completed	`NCT00393341` - Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer	N/A
Completed	`NCT04566458` - RWD Study in HER2+ mBC Patients in Third-Line Therapy
Recruiting	`NCT06075810` - A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer	Phase 1
Recruiting	`NCT04697043` - The Benefit of Surgery in Stage IV of Breast Cancer	N/A
Recruiting	`NCT05837533` - Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients	N/A
Active, not recruiting	`NCT03324425` - Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05670054` - Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients	Phase 3
Terminated	`NCT03202446` - Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.